Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.

Source link

Related posts

Researchers uncover a potentially promising strategy to target brain tumors


darleeeene: MRI of a brain with a tumor.


Thyroid Balance – Your Key To Brain And Body Harmony


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World